Oncology News

BOSTON — Patients taking metformin may be at reduced risk for hepatocellular carcinoma, according to data presented at The Liver Meeting.

BOSTON — Overall survival rates of patients with hepatocellular carcinoma increased markedly between 1977 and 2006, but improvement was impacted by factors including age and ethnicity, according to data presented at The Liver Meeting.

BOSTON — Patients taking statins may be at a reduced risk for developing hepatocellular carcinoma compared with nonusers, according to data presented at The Liver Meeting.

BOSTON — Elizabeth A. Pomfret, MD, PhD, discussed the prioritization of patients with hepatocellular carcinoma for liver transplantation during a lecture at The Liver Meeting.

BOSTON — Ki-67 immunohistochemical staining may predict the risk for developing noncirrhotic hepatocellular carcinoma in patients with HCV, according to data published at the Liver Meeting 2012.

Patients with chronic hepatitis C treated with interferon or pegylated interferon were less likely to develop hepatocellular carcinoma than patients not receiving antiviral therapy in a recent study.

Patients with hepatocellular carcinoma and HIV had better-preserved liver function and presented with earlier-stage cancer but had similar survival rates to those without HIV in a recent study.

Patients with hepatocellular carcinomas treated with percutaneous radiofrequency ablation experienced frequent tumor recurrences but had high 10-year survival rates in a recent study.

Type 2 diabetes can increase the risk for hepatocellular carcinoma and other malignancies in patients with chronic HCV, according to recent results.

Results from a recent study indicated associations between CXCR4 positivity and reduced survival time and early liver recurrence in patients who underwent resection for pancreatic adenocarcinoma.